Context Therapeutics Inc. (NASDAQ:CNTX) Stock Has Average Price Target of $6.40

Shares of Context Therapeutics Inc. (NASDAQ:CNTX) have received a consensus recommendation of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $6.40.

A number of analysts have recently issued reports on the company. Weiss Ratings raised Context Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, October 15th. Zacks Research raised Context Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 10th. Lifesci Capital lowered Context Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Citigroup reissued an “outperform” rating on shares of Context Therapeutics in a research report on Thursday, August 6th. Finally, Wall Street Zen downgraded shares of Context Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 20th.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CNTX. Sanctuary Advisors LLC bought a new position in shares of Context Therapeutics in the 1st quarter valued at $51,000. Two Sigma Securities LLC boosted its stake in Context Therapeutics by 388.7% during the second quarter. Two Sigma Securities LLC now owns 61,444 shares of the company’s stock valued at $34,000 after buying an additional 48,871 shares during the period. Squarepoint Ops LLC purchased a new stake in shares of Context Therapeutics in the 2nd quarter valued at $29,000. Bank of America Corp DE purchased a new stake in Context Therapeutics in the 2nd quarter worth approximately $30,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in Context Therapeutics during the 1st quarter valued at about $211,000. 14.03% of the stock is owned by institutional investors.

Context Therapeutics Price Performance

Context Therapeutics stock traded down $0.02 during midday trading on Friday, reaching $0.18. 933,187 shares of the company traded hands, compared to its average volume of 1,536,840. Context Therapeutics has a 12 month low of $0.18 and a 12 month high of $3.62. The business has a 50 day moving average of $0.28 and a two-hundred day moving average of $1.37. The firm has a market capitalization of $16.61 million, a price-to-earnings ratio of -0.39 and a beta of 1.77.

Context Therapeutics (NASDAQ:CNTX) last issued its earnings results on Tuesday, November 10th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. As a group, equities analysts forecast that Context Therapeutics will post -0.44 EPS for the current year.

Context Therapeutics Company Profile

Context Therapeutics is a clinical-stage biopharmaceutical company developing treatments for solid tumors. The company’s research focuses on bispecific antibodies designed to direct immune cells toward cancer cells. Its pipeline includes CTIM-76, a T-cell-engaging bispecific antibody targeting claudin 6, a protein found on certain tumor cells. Context has also been developing CT-95, which targets mesothelin, another protein expressed by some solid tumors. Founded with an initial focus on therapies for women’s cancers, Context has since broadened its work to address a range of solid tumors.